Beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer

Li-feng Wang, Hai-tao Yin, Xiao-ping Qian, Jia Wei, Yang Zhao, Li-xia Yu, Bao-rui Liu

Abstract


Purpose: Despite the success of docetaxel as an anti-tumour agent, the inter-individual variability in drug response still poses a major impediment to further use of this agent in the treatment of cancer. Current knowledge about predictive biomarkers of docetaxel sensitivity in malignant effusions is poor. The aim of this study was to investigate the association between ?-tubulin III mRNA expression and chemosensitivity to docetaxel in metastatic malignant effusions.

Methods: Real-time quantitative PCR was used for analysis of ?-tubulin III mRNA expression in 37 malignant effusions collected prospectively. Viable tumour cells obtained from malignant effusions were tested for sensitivity to docetaxel using ATP-TCA assay.

Results: ?-tubulin III expression was inversely correlated with sensitivity to docetaxel in pleural effusions of NSCLC patients (P =0.022). The lower level of ?-tubulin III mRNA expression in malignant effusions was associated with higher chemosensitivity to docetaxel in NSCLC patients in vitro. No correlation was found between ?-tubulin III mRNA expression and docetaxel sensitivity in malignant effusions of gastric cancer patient.

Conclusion: Our results demonstrated that ?-tubulin III mRNA expression level in malignant effusions, in which all cancer cells were metastatic, was correlated with docetaxel sensitivity in NSCLC. This highlights the potential role of biomarkers in malignant effusions in further customized chemotherapy.

Full Text:

PDF


DOI: http://dx.doi.org/10.25011/cim.v32i6.10663

Refbacks

  • There are currently no refbacks.


© 2007-2017 Canadian Society for Clinical Investigation.
C.I.M. provides open access to all of its content 6 months after the date of publication